CoChat

Effects of insulin vs. glibenclamide in recently diagnosed patients with type 2 diabetes: a 4‐year follow‐up

Alvarsson, M., Sundkvist, G., Lager, I., Berntorp, K., Fernqvist‐Forbes, E., Steen, L., Örn, T., Holberg, M. A., Kirksæther, N., Grill, V. · 2008 · Diabetes, Obesity and Metabolism
Cited by 60

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Aim: To compare effects of early insulin vs. glibenclamide treatment on beta‐cell function, metabolic control and quality of life (QL) in recently diagnosed patients with type 2 diabetes. Methods: Forty‐nine patients with type 2 diabetes diagnosed 0–2 years before inclusion were randomized to two daily injections of premixed 30% soluble and 70% NPH insulin or glibenclamide at six diabetic clinics in Sweden. C‐peptide–glucagon tests were performed yearly after 3 days of withdrawal of treatment. Results: Thirty‐four patients completed 4 years of study. Daily dose of insulin was increased from 20.4 ± 1.8 U at year 1 to 26.1 ± 2.9 U at year 4 (p = 0.005). Glibenclamide dosage increased from 2.7 ± 0.4 mg at year 1 to 4.5 ± 0.8 mg at year 4 (p = 0.02). Weight increased more in insulin than in glibenclamide treated (+4.4 ± 0.8 vs. +0.3 ± 1.0 kg, p < 0.005). Following short‐term withdrawal of treatment, the C‐peptide responses to glucagon were significantly higher in the insulin vs. glibenclamide group at years 1 (p < 0.01) and 2 (p < 0.02). HbA1c improved identical during the first year but thereafter deteriorated in the glibenclamide group (p < 0.005 for difference at year 4). Ratios of proinsulin to insulin were higher during treatment in glibenclamide‐ vs. insulin‐treated patients after year 2. QL after 4 years as measured by the MOS 36‐item Short‐Form Health Survey (SF‐36) form was not significantly altered. Conclusions: In a 4‐year perspective, beta‐cell function deteriorated in both groups. However, deterioration occurred faster in the glibenclamide group, indicating that alleviating demands on secretion by insulin treatment is beneficial.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2007.00719.x

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 60

Metadata

Authors
Alvarsson, M., Sundkvist, G., Lager, I., Berntorp, K., Fernqvist‐Forbes, E., Steen, L., Örn, T., Holberg, M. A., Kirksæther, N., & Grill, V.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2007-03-29
Volume
10
Issue
5
Pages
421-429
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2024337179
Cited by
60
References
2
FWCI
2.84
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of insulin vs. glibenclamide in recently diagnosed patients with type 2 diabetes: a 4‐year follow‐up. https://app.cochat.ai/papers/10.1111/j.1463-1326.2007.00719.x
The paper
Alvarsson, M., Sundkvist, G., Lager, I., Berntorp, K., Fernqvist‐Forbes, E., Steen, L., Örn, T., Holberg, M. A., Kirksæther, N., & Grill, V. (2008). Effects of insulin vs. glibenclamide in recently diagnosed patients with type 2 diabetes: a 4‐year follow‐up. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2007.00719.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.